In addition, brigatinib, which contains a phenylphosphine oxide motif and serves as an anaplastic lymphoma kinase (ALK) inhibitor, has been achieved commercial success for treating metastatic non-small-cell lung cancer (NSCLC)5. This evidence concerns the gene ALK and non-small cell lung carcinoma.